Cart
sales@molnova.com
NU-2058
CAS No. 161058-83-9
NU-2058( O6-cyclohexylmethyl guanine | NU2058 | NU 2058 )
Catalog No. M12326 CAS No. 161058-83-9
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 190 | In Stock |
|
| 100MG | 295 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNU-2058
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.
-
DescriptionAn ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM; reduces CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and proliferatio in both anti-estrogen-sensitive and resistant cells; also inhibits DNA topoisomerase II ATPase activity (IC50=300 uM).
-
In VitroNU2058 (O6-(Cyclohexylmethyl)guanine) is a competitive inhibitor of CDK2 with respect to ATP (Ki value CDK2, 12 μM) that binds in the ATP binding pocket in a different orientation from other purine-based inhibitors, including olomoucine and roscovotine. NU2058 is the lead compound in a structure-based drug discovery program to develop more potent and selective CDK inhibitors.
-
In Vivo——
-
SynonymsO6-cyclohexylmethyl guanine | NU2058 | NU 2058
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK1|CDK2|TopoII
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number161058-83-9
-
Formula Weight247.2963
-
Molecular FormulaC12H17N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESNC1=NC(OCC2CCCCC2)=C3N=CNC3=N1
-
Chemical Name9H-Purin-2-amine, 6-(cyclohexylmethoxy)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Arris CE, et al. J Med Chem. 2000 Jul 27;43(15):2797-804.
2. Johnson N, et al. Br J Cancer. 2010 Jan 19;102(2):342-50.
3. Harrison LR, et al. Biochem Pharmacol. 2009 May 15;77(10):1586-92.
molnova catalog
related products
-
Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
CDK2 inhibitor 73
A potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM).
-
JNJ-7706621
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
